Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment
View Patent ↗A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.
1. A kit for determining the presence of monomeric brain associated human glutamine synthetase in a body fluid of a patient diagnosed with mild cognitive impairment (MCI) comprising:
at least one antibody that binds monomeric brain associated human glutamine synthetase having a weight of about 44 kDa, wherein said antibody is selected from the group consisting of the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3339 and the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3340, said antibody immobilized on a solid support;
wherein an elevated presence of said monomeric brain associated human glutamine synthetase in said body fluid of said patient diagnosed with mild cognitive impairment (MCI) is associated with an elevated risk of developing Alzheimer's dementia.
2. The kit of claim 1 , further comprising at least one second antibody, wherein said second antibody binds to said monomeric brain associated human glutamine synthetase.
3. The kit of claim 1 , wherein said first antibody is the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3339.
4. The kit of claim 1 , wherein said first antibody is the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3340.
5. A method of diagnosing or monitoring patients having mild cognitive impairment (MCI) for being at an elevated risk of developing Alzheimer's dementia comprising:
obtaining a sample of blood, a blood product or cerebrospinal fluid from a patient diagnosed with mild cognitive impairment;
contacting said sample with an antibody, wherein said antibody binds monomeric brain associated human glutamine synthetase having a weight of about 44 kDa, wherein said antibody is selected from the group consisting of the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3339 and the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3340;
detecting binding of the antibody to the sample;
wherein detection of an elevated level of said glutamine synthetase in the sample from the patient relative to control samples indicates a diagnosis of an elevated risk of Alzheimer's dementia;
wherein an elevated presence of said monomeric brain associated human glutamine synthetase in the sample of said patient diagnosed with mild cognitive impairment (MCI) is associated with being at an elevated risk of developing Alzheimer's dementia.
6. The method of claim 5 , wherein said antibody is the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3339.
7. The method of claim 5 , wherein said antibody is the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3340.
8. The method of claim 5 wherein said step of detecting includes at least one direct or indirect immunoassay selected from the group consisting of a competitive binding assay, a non-competitive binding assay, a radioimmunoassay, an enzyme-linked immunosorbent assay (ELISA), a sandwich assay, a precipitin reaction, a gel diffusion immunodiffusion assay, an agglutination assay, a fluorescent immunoassay, chemiluminescence immunoassay, immunoPCR immunoassay, a protein A or protein G immunoassay, and an immunoelectrophoresis assay.